Cargando…
De-escalating postoperative radiation therapy after primary systemic therapy in cT1-2N1 breast cancer: lesson from the RAPCHEM/BOOG 2010-03 trial
Autores principales: | Banini, Marco, Visani, Luca, Livi, Lorenzo, Meattini, Icro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477657/ https://www.ncbi.nlm.nih.gov/pubmed/37675297 http://dx.doi.org/10.21037/atm-23-1051 |
Ejemplares similares
-
Is radiotherapy after primary chemotherapy (RAPCHEM) on the right path to de-escalation?
por: Socha, Joanna, et al.
Publicado: (2023) -
The Italian Association for Radiotherapy and Clinical Oncology (AIRO) position statements for postoperative breast cancer radiation therapy volume, dose, and fractionation
por: Meattini, Icro, et al.
Publicado: (2022) -
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)
por: de Groot, S., et al.
Publicado: (2015) -
Special issue. De-escalation of loco-regional treatment in breast cancer: Time to find the balance? Partial breast irradiation
por: Meattini, Icro, et al.
Publicado: (2023) -
Fully automated volumetric modulated arc therapy technique for radiation therapy of locally advanced breast cancer
por: Marrazzo, Livia, et al.
Publicado: (2023)